The order carried out as a part of the project titled:
– ARG: “PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ARGINASE INHBITOR FOR CANCER IMMUNOTHERAPY” (POIR.01.01.01-00-0415/17)
co-financed by European Union Funds and because of the competitiveness principle.
We hereby look for Contractor ready to perform:
Development of formulation and manufacturing of investigational medicinal product (IMP) in accordance to Good Manufacturing Practice for clinical trials of phase I & II.
On February 23, 2021, the Ordering Party has updated Appendix No. 5 in connection with the change of share capital. The deadline for submitting offers remains unchanged.
In connection with the questions received to the request for quotation we provide answers to all uncertainties that have arisen before the deadline for submitting questions: